A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab

Authors
Category Primary study
JournalBlood
Year 2022
This article has no abstract
Epistemonikos ID: de3e5f7f5c9745ccf03c48ced672dc33f88e481d
First added on: Feb 16, 2025